Calendrier de promotion Bionomics Limited
Calendrier prolongé
Calendrier simple
Les principaux paramètres
La monnaie du rapport
aud
Grade
Sous-estimation
| Nom |
Signification |
Grade |
| P/S |
1637.83 |
1 |
| P/BV |
1.09 |
9 |
| P/E |
0 |
0 |
Efficacité
| Nom |
Signification |
Grade |
| ROA |
-74.06 |
0 |
| ROE |
-96.08 |
0 |
| ROIC |
0 |
0 |
Dividendes
| Nom |
Signification |
Grade |
| Rendement des dividendes |
0 |
0 |
| DSI |
0 |
0 |
| La croissance moyenne des dividendes |
0 |
0 |
Devoir
| Nom |
Signification |
Grade |
| Debt/EBITDA |
-0.0343 |
10 |
| Debt/Ratio |
0.0104 |
10 |
| Debt/Equity |
0.2973 |
10 |
Pouls de croissance
| Nom |
Signification |
Grade |
| Revenus, milliards, % |
-99.41 |
0 |
| Ebitda, % |
-0.1573 |
0 |
| EPS, % |
73.47 |
8 |
Prix
|
Prix |
Min. |
Max. |
Changement |
Changements dans l'industrie |
Changements dans l'index |
| Hier |
0.006 $ |
0 $ |
0 $ |
0 % |
0 % |
0 % |
| Semaine |
0.006 $ |
0 $ |
0 $ |
0 % |
0 % |
0 % |
| Mois |
0.006 $ |
0 $ |
0 $ |
0 % |
0 % |
0 % |
| 3 mois |
0.006 $ |
0.006 $ |
0.006 $ |
0 % |
0 % |
0 % |
| Six mois |
0.006 $ |
0.006 $ |
0.006 $ |
0 % |
0 % |
0 % |
| Année |
0.006 $ |
0.006 $ |
0.006 $ |
0 % |
0 % |
0 % |
| 3 ans |
0.0332 $ |
0.0013 $ |
0.055 $ |
-81.93 % |
0 % |
0 % |
| 5 ans |
0.049 $ |
0.0013 $ |
0.33 $ |
-87.76 % |
0 % |
0 % |
| 10 ans |
0.0013 $ |
0.0013 $ |
0.61 $ |
+461.54 % |
0 % |
0 % |
| Année à ce jour |
0.006 $ |
0.006 $ |
0.006 $ |
0 % |
0 % |
0 % |
Entreprises similaires
P/E & P/BVEV/Ebitda & Debt/Ebitda
La gestion de l'entreprise
| Superviseur |
Titre d'emploi |
Paiement |
Année de naissance |
| Dr. Errol B. De Souza Ph.D. |
Exec. Chairman |
|
1953 (72 années) |
| Mr. Adrian Hinton BEC, F.C.A. |
Acting Chief Financial Officer |
|
1952 (73 années) |
| Mr. Connor Bernstein M.Sc. |
VP of Strategy & Corp. Devel. |
|
1988 (37 années) |
| Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. |
Consultant Chief Medical Officer of Clinical Neuroscience |
|
|
| Ms. Suzanne Irwin B.Com., FCIS |
Company Sec. |
|
|
Informations sur l'entreprise
À propos de l'entreprise Bionomics Limited
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
MAX Chat
